Crystalline form of omeprazole

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C546S273700

Reexamination Certificate

active

06384059

ABSTRACT:

FIELD OF THE INVENTION
The present invention relates to a novel crystalline form of 5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1
H
-benzimidazole 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1
H
-benzimidazole is known under the generic name omeprazole and its novel crystalline form is hereinafter referred to as omeprazole form A. Further, the present invention also relates to use of omeprazole form A for the treatment of gastrointestinal disorders, pharmaceutical compositions containing omeprazole form A and processes for the preparation of omeprazole form A.
BACKGROUND OF THE INVENTION PRIOR ART
The compound 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1
H
-benzimidazole, having the generic name omeprazole, as well as therapeutically acceptable salts thereof, are described in EP 5129. The single crystal X-ray data and the derived molecular structure of the so far only known crystal form of omeprazole is described by Ohishi et al., Acta Cryst. (1989), C45, 1921-1923. This published crystal form of omeprazole is hereinafter referred to as omeprazole form B.
Omeprazole is a proton pump inhibitor, i.e. effective in inhibiting gastric acid secretion, and is useful as an antiulcer agent. In a more general sense, omeprazole may be used for treatment of gastric-acid related diseases in mammals and especially in man.


REFERENCES:
patent: 4337257 (1982-06-01), Junggren et al.
patent: 4738974 (1988-04-01), Brändström
patent: 5314506 (1994-05-01), Midler et al.
patent: 5690960 (1997-11-01), Bengtsson et al.
patent: 5714505 (1998-02-01), Hasselkus
patent: 5856493 (1999-01-01), Ward et al.
patent: 5877192 (1999-03-01), Lindberg et al.
patent: 5900424 (1999-05-01), Källstrom et al.
patent: 5129 (1981-04-01), None
patent: 533752 (1992-06-01), None
patent: 9722603 (1997-06-01), None
patent: 9821201 (1998-05-01), None
patent: 9925711 (1999-05-01), None
Cairns et al., Journal of Chromatography,. “Enantioselective high performance liquid chromatographic determination of omeprazole in human plasma”, pp. 323-328 (1995).
Erlandsson et al., Journal of Chromatography, “Resolution of the enantiomers of omeprazole and some analogues by liquid chromatography on a trisphenylcarbamoylcellulose-based stationary phase; The effect of the enantiomers of omeprazole on gastric glands”, pp. 305-319 (1990).
Ohishi et al., “Structure of 5-Methoxy-2-{[-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfiny}-1H-benzimidazole (Omeprazole)”, pp. 1921-1323 (1989).
Heneck et al., “Polymorphie von Arzneistoffen”, Pharm. Ind., 59, 1997, 165-169 CN 1160050.
Brändström, A. et al., “Structure activity relationships of substituted benzimidazoles”, Scandinavian Journal of Gastroenterology, 20: Supplemental 108, 15-22 (1985).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Crystalline form of omeprazole does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Crystalline form of omeprazole, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystalline form of omeprazole will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2899528

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.